Recruiting
Phase 3

ELVN-001 vs. TKI

Sponsor:

Enliven Therapeutics

Code:

NCT07905183

Conditions

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ELVN-001

TKI

Study Details

Brief summary:

The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.

Conditions

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML

Study ID

NCT07905183

Start date

Dec 31, 2026

Status verified date

Nov, 2026

Completion date

Jul, 2033

Anticipated

Primary completion date

Dec 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or female at least 18 years of age
  • Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
  • Prior treatment with 1 or more BCR::ABL1 TKI(s)
  • Failure or intolerance on the immediate prior TKI
  • Adequate end organ function as measured by blood tests

Exclusion Criteria:

  • Known T315I mutation
  • Known second chronic phase of CML after previous progression to accelerated or blast phase
  • Any serious or uncontrolled medical disorder
  • QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
  • Previous treatment with a hematopoietic stem-cell transplantation

Study Design

Enrollment

450 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: ELVN-001

ELVN-001

active comparator: Investigator-selected TKI

Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib

Interventions

ELVN-001

ELVN-001 orally daily

TKI

TKI orally daily

Primary outcome measure

  • Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI [ Time Frame: 24 weeks ]

Central Contacts and Locations

Central contacts

Locations

Winship Cancer Institute

Recruiting

Atlanta, Georgia, United States, 30322

Investigative Clinical Research of Indiana, LLC

Recruiting

Indianapolis, Indiana, United States, 46260

Atlantic Health System

Recruiting

Morristown, New Jersey, United States, 07960

Community Center Trials of Utah

Recruiting

Ogden, Utah, United States, 84405

More Information

Sponsor

Enliven Therapeutics

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • Chronic Myeloid Leukemia
  • CML
  • ELVN-001
  • Philadelphia chromosome
  • Tyrosine kinase inhibitor
  • TKI
  • TKIs
  • ENABLE-2
  • Bosutinib
  • Dasatinib
  • Nilotinib
  • Molecular Response
  • BCR::ABL
  • Active site inhibitor of BCR::ABL

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Enliven Therapeutics on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.